Evidence map›Paper›PMID 34308751›Full record

ArticleBioengineered2021

Immune implication of FAM83D gene in hepatocellular carcinoma.

Tao Meng, Zhong Tong, Ming-Ya Yang, Yan Zhang, Yu Liu, Zhen-Zhen Wang, Li-Xin Zhu, Jin Wu

Abstract read
In one paragraph

Article in Bioengineered, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Translational cancer research · 2022
    Article
  9. Article
  10. Pan-cancer and single-cell analysis revealsFrontiers in genetics · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tao MengDepartment of General Surgery and Centre Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Zhong TongDepartment of General Surgery, Hefei City First People's Hospital, Hefei, China.
Ming-Ya YangDepartment of General Surgery and Centre Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Yan ZhangDepartment of General Surgery and Centre Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Yu LiuDepartment of General Surgery and Centre Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Zhen-Zhen WangDepartment of General Surgery and Centre Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Li-Xin ZhuDepartment of General Surgery and Centre Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Jin WuDepartment of General Surgery and Centre Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

FAM83D has been demonstrated to contribute to tumorigenesis. However, its immune effects in hepatocellular carcinoma (HCC) have not been reported. This study aimed to identify the immune role of FAM83D in HCC. FAM83D was over-expressed in HCC and contributed to poor prognosis according to the results of data analysis based on The Cancer Genome Atlas (TCGA). Afterward, the levels of immune cells infiltration were found to be correlated with the expression level of FAM83D in HCC. Through TISIDB and cBioPortal network tools, a total of 82 FAM83D-associated genes were screened out, including 12 immunoinhibitors, 20 immunostimulators and 50 tightly co-expressed genes. TCGA cohort was divided into train set and test set on the basis of the proportion of 7:3. According to FAM83D-associated immunomodulators, a four gene predicted model was established using train set via the Cox regression analysis. Survival analysis demonstrated that the overall survival (OS) of high-risk HCC patients was poor compared with the patients in low-risk group. The reliability and predicted power of the risk-score model were identified by a receiver operating characteristic (ROC) curve. A risk-score based nomogram as well as a calibration curve, which were created could be used to anticipate patient's 1-year, 3-year and 5-year survival probabilities. The test set was used to validate these results. Our findings showed that the FAM83D gene was related with HCC immunity. The immune marker chosen could be a promising biomarker for HCC prognosis.

Indexed as

Carcinoma, HepatocellularCell Cycle ProteinsLiver NeoplasmsMicrotubule-Associated ProteinsAgedBiomarkers, TumorFemaleHumansMaleMiddle AgedPrognosisTranscriptomeBiomarkers, TumorCell Cycle ProteinsFAM83D protein, humanMicrotubule-Associated ProteinsFAM83DHCCimmune cellsnomogramprognosis

Identifiers

PMID34308751
PMCPMC8806426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.